Medicis acquired exclusive U.S. and Canadian rights to the Restylane family of products through certain license agreements in March 2003 and it is covered by a U.S. patent that expires in 2015 or later, the dermatological product maker said in a regulatory filing.
The Restylane products are used to treat facial wrinkles and folds, including the area between the nose and upper lip.
Medicis' non-acne dermatological products, which include Restylane, accounted for 23 percent of the company's sales of $174 million in the June quarter.
The Scottsdale, Arizona-based company also said it amended its 2009 complaint against India's Lupin Ltd related to a copycat version of Medicis' acne treatment Solodyn, to include a newly issued patent.
The company's shares, which have gained 12 percent since the U.S. health regulator approved additional strengths of Solodyn tablets in August, closed at $30.18 Tuesday on the New York Stock Exchange.
No comments:
Post a Comment